Processing math: 100%
World Scientific
Skip main navigation

Cookies Notification

We use cookies on this site to enhance your user experience. By continuing to browse the site, you consent to the use of our cookies. Learn More
×

System Upgrade on Tue, May 28th, 2024 at 2am (EDT)

Existing users will be able to log into the site and access content. However, E-commerce and registration of new users may not be available for up to 12 hours.
For online purchase, please visit us again. Contact us at customercare@wspc.com for any enquiries.
ORAL PRESENTATION: Regenerative Medicine and Stem CellsOpen Access

#145 : Effect of Intra-Ovarian Instillation of Autologous Platelet Rich Plasma on Live Birth Rate in POSEIDON 3 versus POSEIDON 4 Group: A Prospective Follow-Up Study

    https://doi.org/10.1142/S2661318223743461Cited by:0 (Source: Crossref)
    This article is part of the issue:

    Background and Aims: Various anecdotal cases have been reported regarding platelet rich plasma (PRP), demonstrating successful pregnancy outcomes. But the data still remains elusive, especially for women of Asian ethnicity, who have a rapid decline in ovarian reserve when compared to the Caucasian population. We aim to study the effect of intra-ovarian PRP on live birth rate (LBR) in POSEIDON-3 versus POSEIDON-4 group.

    Method: Prospective interventional study conducted at tertiary care institute (July 2020-April 2022). 72-women between 20-40 years with idiopathic poor ovarian reserve (AMH<1.2 ng/ml; AFC<5) and a normal uterine cavity were enrolled. A 1.5 ml-PRP prepared from 30 ml venous-blood, was instilled in each ovarian stroma between day 6-10 of menses with 3-consecutive months follow-up to assess ovarian-reserve parameters (FSH, AMH, AFC). Patients showing improvement (AFC 5) were enrolled in antagonist-IVF cycles and categorised into two groups: POSEIDON-3 vs 4 groups. Paired/signrank test and Independent/ranksum test compared clinical parameters between the two-groups.

    Results: Out of 72 participants, 16.67% responded in 1 st  month of follow-up (AFC: 5 vs 3, p<0.001), 43% in 2 nd  month (AFC: 6 vs 3, p<0.001) and 12.5% in 3 rd  month (AFC:4 vs 3, p<0.001). 20 participants showed no improvement. Excluding one, 43 underwent antagonist-cycle. Although number of oocytes retrieved was similar (6.35 ± 1.83 vs 5.75 ± 1.35, p=0.21), the dose of HMG requirement was higher in POSEIDON-4 (1450 ± 96.53 vs 1190.3 ± 66.49, p=0.04) thus depicting the effect of advanced age. There was no significant difference in dose of rFSH requirement (2705.6 ± 48.93 vs 2737 ± 54.74, p=0.71), fertilisation rate (60.86% vs 57.86%, p=0.66), CPR (25% vs 25.8%, p=0.95) and LBR (22.6% vs 16.66%, p=0.66) between the two-groups.

    Conclusion: Intra-ovarian PRP improves the LBR in low-prognosis patients irrespective of age. PRP improves the ovarian reserve which translates into better reproductive outcomes in a population of women who were planned and counselled for donor-oocyte IVF.

    Publisher's Note:

    This article contains the abstract sections only.